Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kirt Miller

Podiatrist Huntington, WV Doctor of Podiatric Medicine

NPI 1679514673 CMS profile 167114

3075 US Route 60 Ste D230, Huntington, WV 25705

Open in the dashboard

General payments

$5,842

361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirt Miller of Huntington, WV is reported in the CMS Open Payments database as having received $5,842 across 361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $697 36
2024 General $1,138 56
2023 General $753 36
2022 General $1,315 78
2021 General $1,028 73
2020 General $444 30
2019 General $466 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirt Miller
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Kirt Miller were reported at $697. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Kirt Miller Podiatrist median Middle half National median
2019 $466 $196 $72–$601 $163
2020 $444 $118 $38–$335 $114
2021 $1,028 $169 $57–$573 $132
2022 $1,315 $220 $74–$782 $149
2023 $753 $208 $71–$635 $160
2024 $1,138 $237 $87–$681 $164
2025 $697 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $798 33 payments
  2. Novartis Pharmaceuticals Corporation $487 32 payments
  3. Novo Nordisk Inc $397 25 payments
  4. Janssen Pharmaceuticals, Inc $334 36 payments
  5. Relypsa, Inc. $300 26 payments
  6. Paratek Pharmaceuticals, Inc. $243 13 payments
  7. Lilly USA, LLC $228 11 payments
  8. AbbVie, Inc. $226 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $212 14 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $194 11 payments
  11. Other $2,423 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,842 361 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $552 17 payments
  2. LEQVIO $441 29 payments
  3. XARELTO $334 36 payments
  4. LOKELMA $320 12 payments
  5. Ozempic $293 19 payments
  6. Veltassa $275 24 payments
  7. NURTEC ODT $255 15 payments
  8. NUZYRA $243 13 payments
  9. RYBELSUS $235 15 payments
  10. AIRSUPRA $223 4 payments
  11. Other $4,249 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

954

Median for Podiatry: 160

Drug cost

$16,174

Median for Podiatry: $2,368

Branded share of claims

14.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 274 $7,378
Pregabalin Generic 51 $1,826
Allopurinol Generic 146 $1,459
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 52 $896
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 44 $606
Terbinafine Hcl Generic 49 $600
Silver Sulfadiazine Generic 33 $532
Ssd Silver Sulfadiazine Brand 17 $483
Nortriptyline Hcl Generic 22 $442
Colchicine Generic 12 $411

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$98,837

Medicare's payments for the services billed

Medicare patients

502

Average age 75

Services billed

1,739

260 women, 242 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 58%
Chronic kidney disease 39%
Ischemic heart disease 37%
Atrial fibrillation 28%
Depression 28%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $160
$160 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $130
$130 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $108
$108 — —
JARDIANCE
  • Lilly USA, LLC $100
$100 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record